2-(4-甲基-1-哌嗪基)-1-(4-苯乙基苯基)乙酮肟盐酸盐

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 2-(4-甲基-1-哌嗪基)-1-(4-苯乙基苯基)乙酮肟盐酸盐
• 英文名称: hydron;(NZ)-N-[2-(4-methylpiperazin-1-yl)-1-[4-(2-phenylethyl)phenyl]ethylidene]hydroxylamine;chloride
• 化学式: C21H28ClN3O
• 分子量: 373.9
• InChiKey: GHQULUHUJBVDNH-QUABFQRHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.32
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  39.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (Z)-2-(4-methylpiperazin-1-yl)-1-(4-(2-phenylethyl)-phenyl)ethanone oxime 生成 2-(4-甲基-1-哌嗪基)-1-(4-苯乙基苯基)乙酮肟盐酸盐
  参考文献：
  名称：

  Ethanone oximes and pharmaceutical compositions thereof

  摘要：

  以下为Ethanone oximes的通用式：##STR1## 其中R.sup.1代表环烷基、芳基、芳基烷基、芳氧基、芳基氧烷基、芳硫基或芳基磺酰基，这些基团可以选用一个取代基，所述取代基选自具有1至3个碳原子的烷基、具有1至3个碳原子的烷氧基和卤素原子、哌啶基、哌嗪基、4-烷基取代哌嗪基、咪唑基、4-烷基取代咪唑基或取代氨基，R.sup.2代表氢原子或具有1至3个碳原子的烷氧基，R.sup.3代表哌啶基、哌嗪基或4-烷基取代哌嗪基，或者R.sup.1和R.sup.2与它们附着的苯基一起可以形成苯并噻唑-2-基、N-乙酰基苯并噻唑-2-基、噻芘-2-基、二苯并噻吩-3-基、二苯并呋喃-3-基或式的基团：##STR2## 其中R.sup.4代表氢原子或具有1至3个碳原子的烷基，或其药学上可接受的酸盐。它们是一种有效的抗溃疡剂。

  公开号：

  US04977151A1

文献信息

• Ethanone oximes and pharmaceutical compositions thereof
  申请人：Mitsubishi Kasei Corporation

  公开号：US04977151A1

  公开（公告）日：1990-12-11

  Ethanone oximes represented by the following general formula: ##STR1## wherein R.sup.1 represents a cycloalkyl group, aryl group, aralkyl group, aryloxy group, aralkyloxy group, arylthio group or aryl sulfonyl group, those groups being optionally substituted with a substituent selected from an alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms and a halogen atom, piperidino group, piperazino group, 4-alkyl substituted piperazino group, imidazolyl group 4-alkyl substituted imidazolyl group or substituted amino group, R.sup.2 represents a hydrogen atom or an alkoxy group having 1 to 3 carbon atoms, and R.sup.3 represents a piperidino group, piperazino group or 4-alkyl substituted piperazino group, or R.sup.1 and R.sup.2 together with a phenyl group to which they are attached may form a phenothiazin-2-yl group, N-acetyl-phenothiazin-2-yl group, thianthren-2-yl group, dibenzothiophen-3-yl group, dibenzofuran-3-yl group or a group of the formula: ##STR2## wherein R.sup.4 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, or a pharmaceutically acceptable acid addition salts thereof are disclosed. They are a potent antiulcer agent.

  以下为Ethanone oximes的通用式：##STR1## 其中R.sup.1代表环烷基、芳基、芳基烷基、芳氧基、芳基氧烷基、芳硫基或芳基磺酰基，这些基团可以选用一个取代基，所述取代基选自具有1至3个碳原子的烷基、具有1至3个碳原子的烷氧基和卤素原子、哌啶基、哌嗪基、4-烷基取代哌嗪基、咪唑基、4-烷基取代咪唑基或取代氨基，R.sup.2代表氢原子或具有1至3个碳原子的烷氧基，R.sup.3代表哌啶基、哌嗪基或4-烷基取代哌嗪基，或者R.sup.1和R.sup.2与它们附着的苯基一起可以形成苯并噻唑-2-基、N-乙酰基苯并噻唑-2-基、噻芘-2-基、二苯并噻吩-3-基、二苯并呋喃-3-基或式的基团：##STR2## 其中R.sup.4代表氢原子或具有1至3个碳原子的烷基，或其药学上可接受的酸盐。它们是一种有效的抗溃疡剂。
• SECRETIN RECEPTOR AGONISTS TO TREAT DISEASES OR DISORDERS OF ENERGY HOMEOSTASIS
  申请人：Technische Universität München

  公开号：EP3464340A1

  公开（公告）日：2019-04-10
• Secretin Receptor Agonists to Treat Diseases or Disorders of Energy Homeostasis
  申请人：Technische Universität München

  公开号：US20200179488A1

  公开（公告）日：2020-06-11

  The present invention relates to a secretin receptor modulator for use in the prevention and/or treatment of a disease or disorder of energy homeostasis, wherein (a) said secretin receptor modulator is a secretin receptor agonist and said disease or disorder is obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia, high blood pressure or metabolic syndrome, whereby the secretin receptor agonist increases non-shivering thermogenesis in brown adipocytes and/or increases the expression of uncoupling protein 1 (UCP1) in brown adipocytes and/or decreases food intake in a UCP1-dependent manner resulting in the prevention and/or treatment of said disease or disorder; or (b) said secretin receptor modulator is a secretin receptor antagonist and said disease or disorder is cachexia. The invention further relates to a method of increasing non-shivering thermogenesis in brown adipocytes and/or increasing the expression of uncoupling protein 1 (UCP1) in brown adipocytes, to a method of decreasing non-shivering thermogenesis in brown adipocytes, to a method of identifying a secretin receptor agonist capable of increasing non-shivering thermogenesis in brown adipocytes and/or increasing the expression of uncoupling protein 1 (UCP1) in brown adipocytes, to a method of identifying a secretin receptor antagonist capable of decreasing non-shivering thermogenesis in brown adipocytes, to the use of the secretin receptor for screening (a) for secretin receptor agonists that increase non-shivering thermogenesis in brown adipocytes and/or increase the expression of uncoupling protein 1 (UCP1) in brown adipocytes and/or decrease food intake in a UCP1-dependent manner; and/or (b) for secretin receptor antagonists that decrease non-shivering thermogenesis in brown adipocytes, and to the use of a secretin receptor agonist to activate non-shivering thermogenesis in brown adipocytes and/or to increase the expression of uncoupling protein 1 (UCP1) in brown adipocytes and/or to decrease food intake in a UCP1-dependent manner for reducing body weight for cosmetic purposes as well as to the use of a secretin receptor antagonist to decrease thermogenesis in brown adipocytes for increasing body weight for cosmetic purposes.
• [EN] SECRETIN RECEPTOR AGONISTS TO TREAT DISEASES OR DISORDERS OF ENERGY HOMEOSTASIS<br/>[FR] AGONISTES DU RÉCEPTEUR DE LA SÉCRÉTINE POUR TRAITER DES MALADIES OU DES TROUBLES DE L'HOMÉOSTASIE ÉNERGÉTIQUE
  申请人：TECHNISCHE UNIVERSITÄT MÜNCHEN

  公开号：WO2017202851A1

  公开（公告）日：2017-11-30

  The present invention relates to a secretin receptor modulator for use in the prevention and/or treatment of a disease or disorder of energy homeostasis, wherein (a) said secretin receptor modulator is a secretin receptor agonist and said disease or disorder is obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia, high blood pressure or metabolic syndrome, whereby the secretin receptor agonist increases non-shivering thermogenesis in brown adipocytes and/or increases the expression of uncoupling protein 1 (UCP1) in brown adipocytes and/or decreases food intake in a UCP1 -dependent manner resulting in the prevention and/or treatment of said disease or disorder; or (b) said secretin receptor modulator is a secretin receptor antagonist and said disease or disorder is cachexia. The invention further relates to a method of increasing non-shivering thermogenesis in brown adipocytes and/or increasing the expression of uncoupling protein 1 (UCP1 ) in brown adipocytes, to a method of decreasing non-shivering thermogenesis in brown adipocytes, to a method of identifying a secretin receptor agonist capable of increasing non-shivering thermogenesis in brown adipocytes and/or increasing the expression of uncoupling protein 1 (UCP1 ) in brown adipocytes, to a method of identifying a secretin receptor antagonist capable of decreasing non-shivering thermogenesis in brown adipocytes, to the use of the secretin receptor for screening (a) for secretin receptor agonists that increase non-shivering thermogenesis in brown adipocytes and/or increase the expression of uncoupling protein 1 (UCP1 ) in brown adipocytes and/or decrease food intake in a UCP1 -dependent manner; and/or (b) for secretin receptor antagonists that decrease non-shivering thermogenesis in brown adipocytes, and to the use of a secretin receptor agonist to activate non-shivering thermogenesis in brown adipocytes and/or to increase the expression of uncoupling protein 1 (UCP1 ) in brown adipocytes and/or to decrease food intake in a UCP1 -dependent manner for reducing body weight for cosmetic purposes as well as to the use of a secretin receptor antagonist to decrease thermogenesis in brown adipocytes for increasing body weight for cosmetic purposes.